Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

BUY
$179.87 - $225.13 $13,670 - $17,109
76 Added 20.49%
447 $80,000
Q2 2023

Jul 31, 2023

BUY
$178.3 - $266.78 $2,496 - $3,734
14 Added 3.92%
371 $66,000
Q1 2023

May 01, 2023

BUY
$215.53 - $274.5 $76,944 - $97,996
357 New
357 $76,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Knights Of Columbus Asset Advisors LLC Portfolio

Follow Knights Of Columbus Asset Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.